Two Sigma Investments LP Buys Shares of 27,454 Spero Therapeutics Inc (SPRO)

Two Sigma Investments LP bought a new position in Spero Therapeutics Inc (NASDAQ:SPRO) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 27,454 shares of the company’s stock, valued at approximately $169,000. Two Sigma Investments LP owned 0.16% of Spero Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its position in Spero Therapeutics by 27.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 176,483 shares of the company’s stock valued at $1,855,000 after acquiring an additional 37,840 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Spero Therapeutics by 8.9% during the 3rd quarter. BlackRock Inc. now owns 372,469 shares of the company’s stock valued at $3,915,000 after buying an additional 30,470 shares during the period. Stonepine Capital Management LLC bought a new position in shares of Spero Therapeutics during the 3rd quarter valued at $2,380,000. Renaissance Technologies LLC bought a new position in shares of Spero Therapeutics during the 3rd quarter valued at $126,000. Finally, Aquilo Capital Management LLC lifted its holdings in shares of Spero Therapeutics by 91.9% during the 3rd quarter. Aquilo Capital Management LLC now owns 799,691 shares of the company’s stock valued at $8,405,000 after buying an additional 383,000 shares during the period. Institutional investors own 46.32% of the company’s stock.

NASDAQ:SPRO opened at $12.34 on Wednesday. The firm has a market capitalization of $210.38 million, a PE ratio of -4.75 and a beta of 2.97. Spero Therapeutics Inc has a one year low of $5.52 and a one year high of $18.23.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.15. The firm had revenue of $1.69 million during the quarter, compared to analyst estimates of $0.84 million. Spero Therapeutics had a negative return on equity of 43.63% and a negative net margin of 1,050.48%. As a group, research analysts anticipate that Spero Therapeutics Inc will post -3.41 earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on the company. Zacks Investment Research cut Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a report on Friday, March 15th. Oppenheimer set a $30.00 price target on Spero Therapeutics and gave the company a “buy” rating in a report on Tuesday, February 26th. Finally, ValuEngine cut Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $21.80.

WARNING: “Two Sigma Investments LP Buys Shares of 27,454 Spero Therapeutics Inc (SPRO)” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2019/04/17/two-sigma-investments-lp-buys-shares-of-27454-spero-therapeutics-inc-spro.html.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

Featured Article: Capital Gains

Want to see what other hedge funds are holding SPRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spero Therapeutics Inc (NASDAQ:SPRO).

Institutional Ownership by Quarter for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.